{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:15:59Z","timestamp":1788023759456,"version":"build-2784847793"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Elma Research"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thrombopoietin receptor agonists (TPO-RAs) are frequently prescribed as second-line therapy for immune thrombocytopenia (ITP). Approved TPO-RAs have different characteristics that can influence doctor-patient shared decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To gain insight into how ITP and its treatment with subcutaneous TPO-RA are perceived by Italian adults with ITP and by treating hematologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Observational, cross-sectional survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Italian national surveys were conducted in adults with ITP receiving subcutaneous TPO-RA treatment for \u2265 3 months, and separately in hematologists with extensive experience treating ITP. The ITP-PAQ questionnaire captured the impact of ITP and treatments. The patient survey assessed self-reported treatment adherence, setting of TPO-RA administration, administration autonomy, and collected demographic and disease-related data. Methodologic limitations include potential selection bias, absence of a comparison group, and reliance on patient-reported adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between December 2023 and February 2024, the surveys were completed by 50 clinicians and 78 patients distributed across Italy; mean patient age 55.5 (\u00b113.7) years, mean disease duration 2.4 (\u00b12.1) years. Patients were receiving subcutaneous ITP treatment for median 7 (minimum 3\u2013maximum 50) months. The mean total ITP-PAQ score was 70.1\u00b18.5, with approximately 80% of patients reporting little or no impact of ITP on overall quality of life. Most patients (51%) self-administered subcutaneous therapy at home; 27% went to hospital. Overall self-reported adherence was 97%. After the first months of treatment, 90% of patients reported being \u201cextremely satisfied\u201d\/\u201csatisfied\u201d (68%\/22%). This was maintained at survey, when 95% patients were \u201cextremely satisfied\u201d\/\u201csatisfied\u201d (72%\/23%). Satisfaction was highest with home self-administration (p=0.09). There were no significant differences (90% confidence level) in patients\u2019 and clinicians\u2019 responses regarding the main advantages of weekly administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both patients and specialists indicated that the high satisfaction may be associated with perceived advantages of weekly TPO-RA subcutaneous administration, which may be associated with improved adherence to therapy and reduced medication burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261481214","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:59:36Z","timestamp":1787774376000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy"],"prefix":"10.1177","volume":"17","author":[{"given":"Esther Natalie","family":"Oliva","sequence":"first","affiliation":[{"name":"London North West University Healthcare NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Borchiellini","sequence":"additional","affiliation":[{"name":"AOU Citt\u00e0 della Salute e della Scienza - Molinette Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carli","sequence":"additional","affiliation":[{"name":"\u201cS. Bortolo\u201d Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Consoli","sequence":"additional","affiliation":[{"name":"ARNAS Garibaldi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-5311","authenticated-orcid":false,"given":"Alessandro","family":"Lucchesi","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[{"name":"University of Palermo"},{"name":"Hospital \u201cV. Cervello\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ricco","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[{"name":"Catholic University"},{"name":"Fondazione Policlinico A. Gemelli IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Santoro","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Policlinico Umberto I"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria of Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-3954","authenticated-orcid":false,"given":"Monica","family":"Carpenedo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Molecular Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1995347"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102345"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01247.x"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14915"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578336"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1669329"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07615.x"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18291"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26045"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26036"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1548930"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206422"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2024.2024.0055"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073275"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60203-2"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15573"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287408"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2318345"},{"key":"e_1_3_7_23_2","unstructured":"European Medicines Agency. Nplate INN - romiplostim - Summary of Product Characteristics 2009. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nplate-epar-product-information_en.pdf"},{"key":"e_1_3_7_24_2","unstructured":"European Medicines Agency. Revolade INN - eltrombopag - Summary of Product Characteristics 2010. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revolade-epar-product-information_en.pdf"},{"key":"e_1_3_7_25_2","unstructured":"European Medicines Agency. Doptelet INN - avatrombopag - Summary of Product Characteristics 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/doptelet-epar-product-information_en.pdf"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1531824"},{"key":"e_1_3_7_27_2","unstructured":"Italian Medicines Agency. Romiplostim - AIFA label. https:\/\/api.aifa.gov.it\/aifa-bdf-eif-be\/1.0.0\/organizzazione\/2317\/farmaci\/39002\/stampati?ts=RCP&utm_source=chatgpt.com"},{"key":"e_1_3_7_28_2","unstructured":"Italian Medicines Agency. Eltrombopag - DECRETO-LEGGE 13 SETTEMBRE 2012 N. 158. https:\/\/www.aifa.gov.it\/documents\/20142\/2959517\/Determina-PRES-722-2025_ELTROMBOPAG.pdf"},{"key":"e_1_3_7_29_2","unstructured":"Italian Medicines Agency. Avatrombopag - I DETERMINA 9 maggio 2022. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2022-05-23&atto.codiceRedazionale=22A03007&elenco30giorni=true#:\u223c:text=Regime_di_rimborsabilita\u2019_e_prezzo del_23%2D05%2D2022"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2375177"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56120667"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61010153"},{"key":"e_1_3_7_33_2","volume-title":"Adherence to long-term therapies: evidence for action","author":"Sabat\u00e9 E","year":"2003","unstructured":"Sabat\u00e9 E. Adherence to long-term therapies: evidence for action. World health organization, 2003."},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-11"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802377461"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.05.005"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06737-1"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267342"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25776"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S301010"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2253069"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S505337"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261481214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261481214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261481214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:19:13Z","timestamp":1788020353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261481214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["10.1177\/20406207261481214"],"URL":"https:\/\/doi.org\/10.1177\/20406207261481214","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20406207261481214"}}